Even though sorafenib is effective, the resistance of AML to sorafenib occurs in patients and can be characterized by increased expression of several genes that include ALDH1A1, JAK3 (Janus kinase 3), and MMP15 (matrix metallopeptidase 15) [87]. This evidence concerns the gene JAK3 and acute myeloid leukemia.